Dipna Pharmachem Q2 FY26 – Profitability Surges Despite Lower Revenue

Dipna Pharmachem reported a mixed September 2025 quarter — while sales declined YoY, strong improvement in margins led to a sharp rise in EBIDT, net profit, and EPS. • Sales: ↓ 19% YoY to ₹73.5 crore (vs ₹90.6 crore in Sep 2024) • EBIDT: ↑ 97% YoY to ₹2.91 crore (vs ₹1.48 crore) • Net Profit: ↑ 315% YoY to ₹1.41 crore (vs ₹0.34 crore) • EPS: ↑ 321% YoY to ₹0.59 (vs ₹0.14) At a price of ₹15.9, market cap ₹38.3 crore, and PE 18.7, Dipna Pharmachem showcases improving cost efficiencies and profitability despite revenue contraction.